AmplifyBio is a preclinical contract research organization (CRO) that provides drug discovery, characterization, and manufacturing services for small molecules, cell and gene therapies, and mRNA. The company addresses the need for efficient and scalable R&D solutions by offering end-to-end support from in vitro and in vivo safety studies to GMP manufacturing.
Funding
$399.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug development companies often face challenges in efficiently and cost-effectively conducting preclinical research and development, including drug discovery, characterization, safety studies, and manufacturing. These processes require specialized expertise, infrastructure, and adherence to stringent regulatory guidelines, which can be particularly burdensome for smaller biopharmaceutical firms.
Solution
AmplifyBio is a contract research organization (CRO) and contract development and manufacturing organization (CDMO) that provides comprehensive preclinical services to support drug development across various modalities, including small molecules, cell and gene therapies, and mRNA. The company offers integrated solutions spanning drug discovery, characterization, optimization, in vitro and in vivo safety studies, and GMP manufacturing. By outsourcing these activities to AmplifyBio, pharmaceutical companies can accelerate their R&D timelines, reduce operational costs, and access specialized expertise without the need for extensive in-house infrastructure.
Target Audience
AmplifyBio primarily serves pharmaceutical and biotechnology companies, ranging from startups to established firms, that require preclinical R&D and manufacturing services for drug development.
Features
- Integrated preclinical services encompassing drug discovery, characterization, and optimization (ADOC).
- Comprehensive safety, efficacy, and toxicology studies (ASET) adhering to regulatory standards.
- Manufacturing Enablement Center (AMEC) providing flexible contract staffing models for various manufacturing requirements.
- GMP manufacturing capabilities for mRNA therapeutics, from sequence design to final product.
- End-to-end support for cell and gene therapy development, from R&D to scalable manufacturing.
- Validated TCR discovery engine for rapid TCR-T development.
- Scalable and flexible plasmid DNA manufacturing solutions.